Our biotechnology and life sciences patent attorneys act for a variety of clients across the biotechnology and life sciences sector, creating patents for pioneering companies, small start-ups and individual inventors through to big pharma and academic institutions.
Some of the biotechnology patent areas we focus on include:
- Biochemistry
- Bioinformatics
- Biologics
- Diagnostics
- Immunology
- Lab-on-chip microfluidic devices
- Microbiology
- Molecular biology
- Pharmaceutical formulations
- Plant biotechnology
- Plant varieties
- Small molecule pharmaceuticals
- Vaccines
Our team has technical expertise (many to PhD level and beyond) as biochemists, molecular biologists, immunologists, cancer biologists and more. Our experts advise on topics covering all aspects of the biotechnology and life sciences sector, including pharmaceuticals, vaccines, diagnostics, medical devices, and healthcare products and services. We also advise on food and beverages, cosmetics, agriculture and new forms of energy. We are active and involved members of key industry bodies such as The Chartered Institute of Patent Attorneys (CIPA) and International Association for the Protection of Intellectual Property (AIPPI), and we include among our group the current Chair of the AIPPI’s Special Committee 114 on Biotechnology (including Plant Varieties).
We understand that biotechnology and life sciences are fast-moving sectors and that the advice you receive must be one step ahead. Our biotechnology patent attorneys have hands-on experience guiding clients on the most cutting edge and innovative developments in the market, from gene patenting to second medical use claims.
Recent work highlights
Our biotechnology patent attorneys successfully:
- represented a leading international pharmaceuticals company before the European Patent Office (EPO) Board of Appeal in a hugely significant case for the field of personalised medicine;
- defended an innovative genetic analysis company against a European Patent Office (EPO) opposition by a rival corporation;
- assisted a multinational agricultural biotechnology company with the successful defence of European Patent Office (EPO) opposition proceedings, which resulted in a highly advantageous commercial outcome for the client;
- chaired the AIPPI UK group in answering working question Q238 concerning the patentability and enforcement of second medical use claims.